

Claims

[Claim 1.] Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.

[Claim 2.] A compound as described in claim 1, which is in the form of crystals.

[Claim 3.] A compound as described in claim 1 or 2, which is in the form of plate-like crystals.

[Claim 4.] A compound as described in any one of claims 1 to 3, which is in the form of crystals having characteristic peaks of angle of diffraction ( $2\theta$ ), as measured through powder x-ray diffractometry, at 7.2, 17.3, 18.9, 19.4, 20.4, and 21.6 ( $^{\circ}$ ).

[Claim 5.] A compound as described in claim 1 or 2, which is in the form of needles.

[Claim 6.] A compound as described in claim 1, 2, or 5, which is in the form of crystals having characteristic peaks of angle of diffraction ( $2\theta$ ), as measured through powder x-ray diffractometry, at 7.2, 12.9, 17.3, 18.9, 19.8, 21.6, 26.8, and 30.5 ( $^{\circ}$ ).

[Claim 7.] A medicine containing, as an active ingredient, a compound as described in any one of claims 1 to 6.

[Claim 8.] A medicine as described in claim 7, which is a preventive and/or therapeutic drug for a disorder caused by cell adhesion.

[Claim 9.] A medicine as described in claim 8, wherein the disorder caused by cell adhesion is selected from

inflammatory diseases, autoimmune diseases, cancerous metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, and transplantation rejection.

[Claim 10.] A medicine composition containing a compound as described in any one of claims 1 to 6 and a pharmaceutically acceptable carrier therefor.

[Claim 11.] Use of a compound described in any one of claims 1 to 6 for manufacturing a medicine.

[Claim 12.] Use described in claim 11, wherein the medicine is a preventive and/or therapeutic drug for a disorder caused by cell adhesion.

[Claim 13.] Use described in claim 12, wherein the disorder caused by cell adhesion is selected from inflammatory diseases, autoimmune diseases, cancerous metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, and transplantation rejection.

[Claim 14.] A method for treating a disorder caused by cell adhesion, characterized by administering a compound described in any one of claims 1 to 6 in an effective dose.

[Claim 15.] A method described in claim 14, wherein the disorder caused by cell adhesion is selected from inflammatory diseases, autoimmune diseases, cancerous metastasis, bronchial asthma, nasal obstruction, diabetes, arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, and transplantation rejection.